Previous 10 | Next 10 |
BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annua...
Palm Beach, FL – October 14, 2021 – FinancialNewsMedia.com News Commentary – The breast cancer drugs market, which has been steadily growing over the past few years, is projected to continue this trend for the next several years. The breast cancer drugs mark...
BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization - Results demonstrate significant cost benefits of using Motixafortide in combination with G-CSF as standard-of-care mobilization th...
BioLineRx Ltd. (BLRX) Q2 2021 Earnings Conference Call August 18, 2021, 10:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors, IR Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Abi Vainstein-Haras - Chief Medical Officer Ella Sorani - Chief Development...
BioLineRx Reports Second Quarter 2021 Financial Results and Provides Corporate Update - Company actively preparing for an NDA submission for Motixafortide in stem cell mobilization targeted for H1 2022 - - Cash and cash equivalents of $66 million at June 30, 2021 - - Man...
ADI,OTCPK:AWLCF,BLRX,DGLY,DQ,EAT,LITE,LOW,NNDM,PLCE,SFL,TGT,TJX,VIPS,WB,ZIM For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Wednesday's open
BioLineRx to Report Second Quarter 2021 Results on August 18, 2021 Management to hold a conference call at 10:00 a.m. EDT PR Newswire TEL AVIV, Israel , Aug. 12, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage bioph...
Today, we have our "Double Down or Diversify" series. We have 13 new ideas that contributors have chosen for the second half of the contest. With a heavy focus on biotech, commodities, and energy - there also are ideas for investors who focus on tech, value, and dividends. F...
Weibo WB +43% on report that Chairman Chao, investor in talks for at least $20B buyout.Bridgeline Digital (BLIN) +35%.BSQUARE (BSQR) +32%.Marin Software (MRIN) +26%.Axcella Health (AXLA) +23%.Odonate Therapeutics (ODT) +21%.Ocugen OCGN +19% Shares extended gains after part...
Alterity Therapeutics Limited (ATHE) +57% on a new patent by USPTO.Birks Group (BGI) +49% on re-opening of its retail stores across Canada.Wunong Net Technology Company (WNW) +46%.Spero Therapeutics (SPRO) +23% on $40M equity investment from Pfizer.Bridgeline Digital (BLIN) +21...
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) PR Newswire - Investigator-initiated study in...
Orkla ASA ADR (ORKLY) is expected to report for Q1 2024 Cosmos Health Inc. (COSM) is expected to report $-0.14 for Q1 2024 Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q1 2024 DCC Plc (DCCPF) is expected to report for Q4 2024 Datatec Ltd ADR (DTTLY)...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting PR Newswire New analysis of biopsy samples demonstrate...